Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 398-404

  Lu, Ching Lan ^a   Hung, Chien Ching ^b   Chuang, Yu Chung ^b   Liu, Wen Chun ^b   Su, Chin Ting ^b   Su, Yi Ching ^b   Chang, Shu Fang ^b   Chang, Sui Yuan ^b   Chang, Shan Chwen ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Combination antiretroviral therapy; HIV infection; Immunogenicity; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Streptococcus pneumoniae

Indexed keywords

23 VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE; 7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RISK FACTOR; SEROLOGY; SEROTYPE; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VIRAL LOAD;

EID: 84874716270     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22836     Document Type: Article

References (29)

1. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20:11-5; PMID:17197876; http://dx.doi.org/10.1097/QCO. 0b013e328012c5f1. (Pubitemid 46052121)
2. Jordano Q, Falco V, Almirante B, Planes AM, del Valle O, Ribera E, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8; PMID:15156452; http://dx.doi.org/10.1086/420933. (Pubitemid 38738561)
3. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS ONE 2011; 6:e27929; PMID:22140487; http://dx.doi.org/10.1371/journal. pone.0027929.
4. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [quiz CE1-4]. MMWR Recomm Rep 2009; 58(RR-4):1-207, quiz CE1-4; PMID:19357635.
5. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-94; PMID:11115712; http://dx.doi.org/10.1016/S0264-410X(00)00232- 2.
6. Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010; 11:54-63; PMID:19659943; http://dx.doi.org/10.1111/j.1468-1293.2009.00744.x.
7. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 1998; 12:1683-9; PMID:9764789; http://dx.doi.org/10.1097/00002030-199813000-00017. (Pubitemid 28418340)
8. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al.23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial Lancet 2000 355 2106-11 PMID:10902624 http://dx.doi.org/10.1016/S0140-6736(00)02377-1. (Pubitemid 30364659)
9. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823. (Pubitemid 36514704)
10. Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67-80; PMID:17974480; http://dx.doi.org/10.1016/S1473-3099(07)70242-6. (Pubitemid 351620930)
11. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIVinfected adults. N Engl J Med 2010; 362:812-22; PMID:20200385; http://dx.doi.org/10.1056/ NEJMoa0903029.
12. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, et al.; COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:499-505; PMID:19556517; http://dx.doi.org/10.1164/rccm.200903-0488OC.
13. Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45:1576-82; PMID:18190318; http://dx.doi.org/10.1086/523583. (Pubitemid 351411841)
14. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53; PMID:11672921; http://dx.doi.org/10.1016/S0264-410X(01)00347-4. (Pubitemid 32973800)
15. Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al.; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34; PMID:18025879; http://dx.doi.org/10.1097/QAD.0b013e3282887e91. (Pubitemid 350145174)
16. Musher DM, Sampath R, Rodriguez-Barradas MC The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011 52 633-40 PMID:21292668 http://dx.doi.org/10. 1093/cid/ciq207.
17. Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, et al.; NIH COPD Clinical Research Network. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012; 55:e35-44; PMID:22652582; http://dx.doi.org/10.1093/cid/cis513.
18. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639-45; PMID:12721944; http://dx.doi.org/10. 1086/374784. (Pubitemid 36578970)
19. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial. Am J Transplant 2007; 7:633-8; PMID:17217436; http://dx.doi.org/10.1111/j.1600-6143.2007.01668.x. (Pubitemid 46376451)
20. Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebocontrolled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47:885-92; PMID:18715160; http://dx.doi.org/10.1086/591537.
21. Lu CL, Chang SY, Sun HY, Liu WC, Tseng YT, Hsieh CY, et al. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy. J Formos Med Assoc 2012; 111:445-51; PMID:22939663; http://dx.doi.org/10.1016/j.jfma.2011.06.027.
22. Penaranda M, Payeras A, Cambra A, Mila J, Riera M; Majorcan Pneumococcal Study Group. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010; 24:1226-8; PMID:20299956; http://dx.doi.org/10.1097/QAD.0b013e3283389de5.
23. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-21; PMID:11850863; http://dx.doi.org/10. 1086/339044. (Pubitemid 34194853)
24. Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, et al.; Pediatric AIDS Clinical Trials Group P1024 Protocol Team. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9; PMID:17006288; http://dx.doi.org/10.1097/01.inf. 0000237830.33228.c3. (Pubitemid 44510587)
25. Lu CL, Hung CC, Chuang YC, Liu WC, Su CT, Hsiao CF, et al. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine 2012; 30:3526-33; PMID:22484349; http://dx.doi.org/10.1016/j.vaccine.2012.03.070.
26. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12; PMID:15121313; http://dx.doi.org/10.1016/j.vaccine.2003.10.030.
27. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Lue HC, et al. Increased prevalence of erythromycin resistance in streptococci: substantial upsurge in erythromycin-resistant M phenotype in Streptococcus pyogenes (1979-1998) but not in Streptococcus pneumoniae (1985-1999) in Taiwan. Microb Drug Resist 2002; 8:27-33; PMID:12002646; http://dx.doi.org/10.1089/10766290252913728.
28. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001 8:266-72; PMID:11238206. (Pubitemid 32217054)
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30; PMID:3719049; http://dx.doi.org/10.2307/2531248